Cibus Inc Ordinary Shares - Class A CBUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.81
- Day Range
- $1.72–1.83
- 52-Week Range
- $1.09–4.19
- Bid/Ask
- $1.78 / $2.41
- Shares Outstanding
- 76.33M
- Market Cap
- $136.63M
- Volume/Avg
- 206,215 / 394,966
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 118
- Website
- https://www.cibus.com
Valuation
|
Metric
|
CBUS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.85 |
Price/Sales | 22.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Profitability
|
Metric
|
CBUS
|
|---|---|
Return on Assets (Normalized) | −27.75% |
Return on Equity (Normalized) | −182.07% |
Return on Invested Capital (Normalized) | −73.30% |
Return on Assets
CBUS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@?>^># | LOCK|@><K% | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|cfn>mv^ | LOCK|SMTg# | $71B | |||
| argenx SE ADR
ARGX
| LOCK|$RSlp&G | LOCK|<qK | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|W@#n%g | LOCK|&p | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#g$G?K | LOCK|<^?t | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Sn%^#$% | LOCK|$!jM% | $26B | |||
| Moderna Inc
MRNA
| LOCK|?hvM#@x | LOCK|p@ | $25B | |||
| Incyte Corp
INCY
| LOCK|$Xx>JV! | LOCK|pQC | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|b$w%$%r | LOCK|HD | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Cxz@%j | LOCK|X&s | $16B |
United States